Clinical Trials Directory

Trials / Unknown

UnknownNCT00002301

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir

Foscarnet Treatment of Cytomegalovirus (CMV) Retinitis in AIDS Patients Not Eligible for Ganciclovir Therapy and Ganciclovir Treatment Failures

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
—
Sponsor
Astra USA · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

To evaluate the safety and efficacy of foscarnet induction treatment of cytomegalovirus (CMV) retinitis in AIDS patients who have previously suffered severe dose-limiting ganciclovir-related myelosuppression, who are ineligible for ganciclovir treatment due to myelosuppression or who have clearly failed to have a therapeutic response to ganciclovir therapy. To assess the duration of clinical response. To evaluate the effect on quantitative CMV cultures of blood and urine. To determine the effect on recovery of HIV p24 antigen capture direct from plasma.

Conditions

Interventions

TypeNameDescription
DRUGFoscarnet sodium

Timeline

First posted
2001-08-31
Last updated
2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00002301. Inclusion in this directory is not an endorsement.